Lates News

According to Every Day AI Express, Guojin Securities issued a research report on April 2, giving a "buy" rating to Sanesco Health (688336.SH). The reasons for the rating mainly include: 1) the main business income has slightly declined, with a confirmed first payment income of 2.826 billion yuan for the 707 project; 2) the core pipeline is steadily advancing, and 2026 will usher in a period of dense pipeline cashing in; 3) early research continues to exert force, with multiple self-immune dual/multi-resistant submissions of IND or in important pre-clinical stages, and expectations for follow-up developments. (Daily Economic News)